

(19)



(11)

EP 3 247 724 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)**Corrections, see****Bibliography INID code(s) 73**

(48) Corrigendum issued on:

16.04.2025 Bulletin 2025/16

(45) Date of publication and mention of the grant of the patent:

12.03.2025 Bulletin 2025/11(21) Application number: **16700518.0**(22) Date of filing: **12.01.2016**

(51) International Patent Classification (IPC):

C07K 16/24 ^(2006.01)

(52) Cooperative Patent Classification (CPC):

C07K 16/244; A01K 67/0278; A61P 31/00;**A61P 37/02; A61P 37/06; A61P 37/08;****A01K 2217/072; A01K 2217/15; A01K 2227/105;****A01K 2267/01; A61K 2039/505; C07K 2317/565;****C07K 2317/569; C07K 2317/92**

(86) International application number:

PCT/GB2016/050070

(87) International publication number:

WO 2016/113557 (21.07.2016 Gazette 2016/29)(54) **IL-17A BINDING PROTEINS**

IL-17A-BINDENDE PROTEINE

PROTÉINES DE LIAISON À IL-17A

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**(30) Priority: **12.01.2015 GB 201500463**

(43) Date of publication of application:

29.11.2017 Bulletin 2017/48

(60) Divisional application:

25162857.4(73) Proprietor: **Crescendo Biologics Limited****Cambridge CB1 2JH (GB)**

(72) Inventors:

- **EDWARDS, Bryan**
Cambridge
Cambridgeshire CB22 3AT (GB)
- **LASHMAR, Ulla**
Cambridge
Cambridgeshire CB22 3AT (GB)
- **MCGUINNESS, Brian**
Cambridge
Cambridgeshire CB22 3AT (GB)

• **ROMANOS, Mike**

Cambridge

Cambridgeshire CB22 3AT (GB)

• **SANDAL, Thomas**

Cambridge

Cambridgeshire CB22 3AT (GB)

• **TENG, Yumin**

Cambridge

Cambridgeshire CB22 3AT (GB)

(74) Representative: **Appleyard Lees IP LLP****15 Clare Road****Halifax HX1 2HY (GB)**

(56) References cited:

WO-A1-2007/149032 WO-A1-2012/156219**WO-A1-2013/063110 WO-A2-2008/021156****WO-A2-2010/102251**

- **MATTHEW ROE: "Superior human single domain VH antibody fragments from a transgenic mouse", BIOPHARMADEALMAKERS, 12 April 2013 (2013-04-12), pages B23, XP055254756, Retrieved from the Internet <URL:http://www.crescendobiologics.com/uploads/news/id11/Nature Biopharma Dealmakers April 2013.pdf> [retrieved on 20160302]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 247 724 B8

- **VANHEUSDEN KATRIEN ET AL: "Pre-Clinical Proof-Of-Concept Of ALX-0761, a Nanobody (R) Neutralizing Both IL-17A and F In a Cynomolgus Monkey Collagen Induced Arthritis Model", ARTHRITIS & RHEUMATISM, WILEY INTERSCIENCE, US, vol. 65, 30 September 2013 (2013-09-30), pages S543, XP009511645, ISSN: 0004-3591, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131>**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification